Target type: molecularfunction
Enables the transfer of carbohydrate derivative from one side of a membrane to the other. [GOC:pr, GOC:TermGenie]
Carbohydrate derivative transmembrane transporter activity is a molecular function associated with proteins that facilitate the movement of carbohydrate derivatives across cell membranes. These molecules can include sugars, polysaccharides, and glycoconjugates. The process involves the binding of the carbohydrate derivative to the transporter protein, followed by a conformational change that allows the molecule to move across the membrane. This transport can occur in either direction, depending on the specific transporter and the concentration gradient of the substrate. Carbohydrate derivative transmembrane transporter activity plays a crucial role in various cellular processes, including nutrient uptake, waste removal, signal transduction, and cell adhesion. These transporters are essential for maintaining cellular homeostasis and are involved in a wide range of biological functions, such as energy production, biosynthesis, and cell-cell communication. Some examples of carbohydrate derivative transmembrane transporters include glucose transporters, lactose permeases, and sialic acid transporters. These proteins exhibit high specificity for their substrates, ensuring efficient and selective transport across the membrane.'
"
| Protein | Definition | Taxonomy |
|---|---|---|
| Multidrug resistance-associated protein 5 | An ATP-binding cassette sub-family C member 5 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O15440] | Homo sapiens (human) |
| Compound | Definition | Classes | Roles |
|---|---|---|---|
| dilazep | dilazep : A member of the class of diazepanes that is 1,4-diazepane substituted by 3-[(3,4,5-trimethoxybenzoyl)oxy]propyl groups at positions 1 and 4. It is a potent adenosine uptake inhibitor that exhibits antiplatelet, antianginal and vasodilator properties. Dilazep: Coronary vasodilator with some antiarrhythmic activity. | benzoate ester; diazepane; diester; methoxybenzenes | cardioprotective agent; platelet aggregation inhibitor; vasodilator agent |
| dipyridamole | dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots. Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol | adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent |
| sulfinpyrazone | Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | pyrazolidines; sulfoxide | uricosuric drug |
| trequinsin | trequinsin: RN given refers to parent cpd; structure given in first source | pyridopyrimidine | |
| l 660,711 | quinolines | ||
| cyclic gmp | 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine. Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed) | 3',5'-cyclic purine nucleotide; guanyl ribonucleotide | Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite |
| sildenafil | sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position. | piperazines; pyrazolopyrimidine; sulfonamide | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent |